I see a solid, though not risk-free, reinsurance case. Q3 revenue rose 10.6% to €6,410M and net income increased 6.7% to €695M; free cash flow grew 18.8% to €2,004M. The 4.3% indicated dividend yield and 54% payout look supportive, while estimated EPS growth slows from 6.5% in 2026 to 3.1% in 2027. At 12.4x trailing earnings, valuation is reasonable, but the median €275.00 target implies 6.0% downside and the shares are only 4.5% below their 52-week high. Net margin fell 0.4 pp, and the supplied data omit solvency and combined-ratio measures, so I cannot confirm underwriting discipline. I would start a modest position, not chase recent momentum: buy with 20% of EUR cash.
Reasonable earnings valuation and dividend support a measured entry despite slowing growth, margin pressure, and limited upside at current prices.